PATENT CLAIM ANALYSIS

Application Number: 16225028
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-07
Patent Classification: ["424", "248100"]

Abstract:
The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.

Claim (Index 33):
The method of  claim 25 , wherein a dose of targeted radiotherapy is applied in a single full dose.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.45455
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13396866', '16112430', '15104890', '15301793', '14138421']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7387345021090763
- 35 USC 102 Novelty (BERT): 0.5296780618186606
- Combined Prediction Score: 0.7178288580800347
- Mean Citation Score: 248.612132
- Max Citation Score: 334.79575
- Similarity Product: 199.05178001651169

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test